HER2 Support Group Forums - View Single Post - preclinical: metronomic chemotherapy (oral) produced remarkable prolongn of survival

Rich66 · 11-14-2009, 01:41 AM

Crit Rev Oncol Hematol. 2009 Aug 1. [Epub ahead of print]
Weekly paclitaxel versus weekly docetaxel in elderly or frail patients with metastatic breast carcinoma: A randomized phase-II study of the Belgian Society of Medical Oncology.

Beuselinck B, Wildiers H, Wynendaele W, Dirix L, Kains JP, Paridaens R.
University Hospitals Leuven, Catholic University Leuven, Medical Oncology Department, Belgium.
This randomized phase-II trial investigated the efficacy and tolerability of weekly docetaxel or paclitaxel in metastatic breast cancer (MBC) patients considered unfit for a 3-weekly therapy. The primary study endpoint was antitumor activity, the second endpoint was tolerability, time to progression (TTP) and overall survival (OS). In intent-to-treat analysis, we observed for paclitaxel and docetaxel respectively partial response (PR) in 48% versus 38%, stable disease (SD) in 24% versus 16%, PD in 15% versus 30%. Median TTP was 21.1 weeks versus 12.7 weeks and median OS 55.7 weeks versus 32 weeks. Toxicity profiles were acceptable with more anemia and neurotoxicity for paclitaxel and more edema and fatigue for docetaxel. In patients with MBC unfit for 3-weekly docetaxel or paclitaxel, weekly administration of either compound may certainly be considered. They display different, but acceptable toxicity profiles, with levels of antitumoral efficacy comparable to those previously reported for 3-weekly regimens.

PMID: 19651523 [PubMed - as supplied by publisher]

???Weekly less effective than tri-weekly???:

Anticancer Res. 2008 Nov-Dec;28(6B):3993-5.
Docetaxel for metastatic breast cancer: two consecutive phase II trials.

Campora E, Colloca G, Ratti R, Addamo G, Coccorullo Z, Venturino A, Guarneri D.
Division of Medical Oncology, "G. Borea" Hospital, Sanremo, Imperia, Italy. e.campora@as11.liguria.it
BACKGROUND: Docetaxel is the most active agent for metastatic breast cancer, but the optimal treatment regimen as a single agent has yet to be defined. PATIENTS AND METHODS: Two consecutive monocentric phase II trials of docetaxel in metastatic breast cancer were carried out. In Trial I, 36 patients received docetaxel 35 mg/m2 weekly for 6 weeks every 8 weeks and in Trial II, 29 patients received docetaxel 100 mg/m2 day 1 every 21 days. RESULTS: Patient characteristics were comparable. However, patients with liver involvement comprised 25% of cases in Trial I and 55% in Trial II. The overall response rate on an intention-to-treat basis was 19% vs. 45% in Trial I and II respectively; time to progression was 3.8 vs. 7.5 months respectively, and overall median survival was comparable in each trial. CONCLUSION: Docetaxel given at 100 mg/m2 every three weeks appears to be a safe, effective regimen that can be applied in common clinical practice for the treatment of metastatic breast cancer.

PMID: 19192662 [PubMed - indexed for MEDLINE]

Oncology. 2009;77(3-4):212-6. Epub 2009 Sep 4.
Weekly docetaxel with or without gemcitabine as second-line chemotherapy in paclitaxel-pretreated patients with metastatic breast cancer: a randomized phase II study conducted by the Hellenic Co-Operative Oncology Group.

Papadimitriou CA, Kalofonos H, Zagouri F, Papakostas P, Bozas G, Makatsoris T, Dimopoulos MA, Fountzilas G.
Department of Clinical Therapeutics, Alexandra Hospital, University of Athens School of Medicine, Athens, Greece.
OBJECTIVE: A randomized phase II trial was conducted to test whether the addition of gemcitabine to weekly docetaxel could improve the objective response rate and survival outcomes as second-line chemotherapy in patients with metastatic breast cancer who have failed a paclitaxel-containing regimen. METHODS: Patients were randomized to receive either weekly docetaxel 40 mg/m(2) (group A, n = 34) or the combination of weekly docetaxel 35 mg/m(2) with gemcitabine 600 mg/m(2) (group B, n = 41). Three consecutive weekly infusions followed by a 1-week rest period represented 1 chemotherapy cycle. RESULTS: The objective response rate was 18% and 27.5% in group A and B, respectively (p = 0.413). No statistically significant differences were demonstrated in terms of median overall survival and time to disease progression. The rate and grade 3 and 4 neutropenia were higher in group B (23 vs. 3%). CONCLUSIONS: The weekly administration of docetaxel and gemcitabine did not result in superior clinical outcomes over weekly docetaxel. Copyright 2009 S. Karger AG, Basel.

PMID: 19729979 [PubMed - indexed for MEDLINE]

11-14-2009, 01:41 AM	#10
Rich66 Senior Member Join Date: Feb 2008 Location: South East Wisconsin Posts: 3,431	Re: preclinical: metronomic chemotherapy (oral) produced remarkable prolongn of survi Crit Rev Oncol Hematol. 2009 Aug 1. [Epub ahead of print] Weekly paclitaxel versus weekly docetaxel in elderly or frail patients with metastatic breast carcinoma: A randomized phase-II study of the Belgian Society of Medical Oncology. Beuselinck B, Wildiers H, Wynendaele W, Dirix L, Kains JP, Paridaens R. University Hospitals Leuven, Catholic University Leuven, Medical Oncology Department, Belgium. This randomized phase-II trial investigated the efficacy and tolerability of weekly docetaxel or paclitaxel in metastatic breast cancer (MBC) patients considered unfit for a 3-weekly therapy. The primary study endpoint was antitumor activity, the second endpoint was tolerability, time to progression (TTP) and overall survival (OS). In intent-to-treat analysis, we observed for paclitaxel and docetaxel respectively partial response (PR) in 48% versus 38%, stable disease (SD) in 24% versus 16%, PD in 15% versus 30%. Median TTP was 21.1 weeks versus 12.7 weeks and median OS 55.7 weeks versus 32 weeks. Toxicity profiles were acceptable with more anemia and neurotoxicity for paclitaxel and more edema and fatigue for docetaxel. In patients with MBC unfit for 3-weekly docetaxel or paclitaxel, weekly administration of either compound may certainly be considered. They display different, but acceptable toxicity profiles, with levels of antitumoral efficacy comparable to those previously reported for 3-weekly regimens. PMID: 19651523 [PubMed - as supplied by publisher] ???Weekly less effective than tri-weekly???: Anticancer Res. 2008 Nov-Dec;28(6B):3993-5. Docetaxel for metastatic breast cancer: two consecutive phase II trials. Campora E, Colloca G, Ratti R, Addamo G, Coccorullo Z, Venturino A, Guarneri D. Division of Medical Oncology, "G. Borea" Hospital, Sanremo, Imperia, Italy. e.campora@as11.liguria.it BACKGROUND: Docetaxel is the most active agent for metastatic breast cancer, but the optimal treatment regimen as a single agent has yet to be defined. PATIENTS AND METHODS: Two consecutive monocentric phase II trials of docetaxel in metastatic breast cancer were carried out. In Trial I, 36 patients received docetaxel 35 mg/m2 weekly for 6 weeks every 8 weeks and in Trial II, 29 patients received docetaxel 100 mg/m2 day 1 every 21 days. RESULTS: Patient characteristics were comparable. However, patients with liver involvement comprised 25% of cases in Trial I and 55% in Trial II. The overall response rate on an intention-to-treat basis was 19% vs. 45% in Trial I and II respectively; time to progression was 3.8 vs. 7.5 months respectively, and overall median survival was comparable in each trial. CONCLUSION: Docetaxel given at 100 mg/m2 every three weeks appears to be a safe, effective regimen that can be applied in common clinical practice for the treatment of metastatic breast cancer. PMID: 19192662 [PubMed - indexed for MEDLINE] Oncology. 2009;77(3-4):212-6. Epub 2009 Sep 4. Weekly docetaxel with or without gemcitabine as second-line chemotherapy in paclitaxel-pretreated patients with metastatic breast cancer: a randomized phase II study conducted by the Hellenic Co-Operative Oncology Group. Papadimitriou CA, Kalofonos H, Zagouri F, Papakostas P, Bozas G, Makatsoris T, Dimopoulos MA, Fountzilas G. Department of Clinical Therapeutics, Alexandra Hospital, University of Athens School of Medicine, Athens, Greece. OBJECTIVE: A randomized phase II trial was conducted to test whether the addition of gemcitabine to weekly docetaxel could improve the objective response rate and survival outcomes as second-line chemotherapy in patients with metastatic breast cancer who have failed a paclitaxel-containing regimen. METHODS: Patients were randomized to receive either weekly docetaxel 40 mg/m(2) (group A, n = 34) or the combination of weekly docetaxel 35 mg/m(2) with gemcitabine 600 mg/m(2) (group B, n = 41). Three consecutive weekly infusions followed by a 1-week rest period represented 1 chemotherapy cycle. RESULTS: The objective response rate was 18% and 27.5% in group A and B, respectively (p = 0.413). No statistically significant differences were demonstrated in terms of median overall survival and time to disease progression. The rate and grade 3 and 4 neutropenia were higher in group B (23 vs. 3%). CONCLUSIONS: The weekly administration of docetaxel and gemcitabine did not result in superior clinical outcomes over weekly docetaxel. Copyright 2009 S. Karger AG, Basel. PMID: 19729979 [PubMed - indexed for MEDLINE] __________________ Mom's treatment history (link)